Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
US Army
Harvard Business School
Teva
Chubb

Generated: August 20, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,486,135

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,486,135
Title: Nucleic acid respiratory syncytial virus vaccines
Abstract:Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
Inventor(s): Li; Xiaomao (Toronto, CA), Ewasyshyn; Mary E. (Thornhill, CA), Sambhara; Suryaprakash (Markham, CA), Klein; Michel H. (Willowdale, CA)
Assignee: Aventis Pasteur Limited (Toronto, CA)
Application Number:09/570,383
Patent Claims:1. A method of using a gene encoding an RSV F protein lacking the transmembrane region to produce an immune response in a host, which comprises: isolating said gene; operatively linking said gene to at least one control sequence to produce a plasmid vector, said control sequence directing expression of said RSV F protein when said vector is introduced into a host to produce an immune response to said RSV F protein; and introducing said vector into the host.

2. The method of claim 1 wherein said at least one control sequence comprises the immediate early cytomegalovirus promoter.

3. The method of claims 1 wherein said gene encoding an RSV F protein encodes an RSV F protein fragment lacking an autologous RSV F signal peptide sequence and includes a sequence encoding a heterologous signal peptide which enhance the level of expression of RSV F protein.

4. The method of claims 3 wherein said gene coding an RSV F protein encoding a signal peptide encodes HSV I gD.

5. The method of claim 4 wherein said at least one control sequence comprises the immediately early cytomegalovirus promoter.

6. The method of claim 5 including the step of: operatively linking said gene to an immunoprotective enhancing sequence which comprises a pair of splice sites to prevent aberrant mRNA splicing to produce an enhanced immunoprotection to said RSV F protein in said host.

7. The method of claim 6 wherein said immunoprotection enhancing sequence is that of rabbit .beta.-globin intron II.

Details for Patent 6,486,135

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Aventis Pasteur Limited (Toronto, CA) 2015-06-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Aventis Pasteur Limited (Toronto, CA) 2015-06-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Aventis Pasteur Limited (Toronto, CA) 2015-06-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
QuintilesIMS
UBS
Citi
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.